Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.

Pathology, research and practice - 1 Dec 2019

Kalfusova Alena, Linke Zdenek, Kalinova Marketa, Krskova Lenka, Hilska Irena, Szabova Jana, Vicha Ales, Kodet Roman

Abstract excerpt

The most important findings revealing pathogenesis, molecular characteristics, genotyping and targeted therapy of gastrointestinal stromal tumors (GISTs) are activated oncogenic mutations in KIT and PDGFRA genes. Imatinib mesylate (IM), which inhibits both KIT and PDGFRA receptors, significantly improved treatment of advanced (metastatic, recurrent, and/or inoperable) GISTs. However, in a significant number of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Genetic Heterogeneity

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Succinate Dehydrogenase

Source

Identifiers

PMID: 31708372
DOI: 10.1016/j.prp.2019.152708

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.PMID 31708372Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

[Gastrointestinal stromal tumor (GIST): advances in 2013].Semantic proximity Read ↗

Update on Molecular Genetics of Gastrointestinal Stromal TumorsSemantic proximity Read ↗

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Semantic proximity Read ↗

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism ResearchSemantic proximity Read ↗

Gastrointestinal Stromal Tumors: The GIST of Precision Medicine.Semantic proximity Read ↗

Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine.Semantic proximity Read ↗

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.